Using our mobile app? Be sure to check for any new app updates to receive any enhancements.
Logo

Get Healthy!

Results for search "Hemophilia".

Health News Results - 7

The U.S. Food and Drug Administration on Thursday approved a costly single-dose gene therapy for patients with severe hemophilia A, a life-threatening hereditary bleeding disorder.

The treatment is not cheap: Roctavian will cost $2.9 million for a single infusion, the Associated Press reported.

"Hereditary hemophilia A is a potentially serious bleeding disorder. Severe case...

An experimental injectable drug appears effective in reducing bleeds in patients with hemophilia A and B, according to a pair of new clinical trials.

Two-thirds of people with treatment-resistant hemophilia who were treated with the drug fitusiran had no bleeds at all after nine months, versus just 5% of people treated with drugs that enhance clotting, according to a trial published onlin...

People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag.

The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov. 22. Soon after, drugmaker CSL Behring revealed its cost.

The company said its drug would ultimately reduce health care costs because patients with the genetic disorder would ne...

People with hemophilia B could find their bleeding risk dramatically reduced with just one injection of an experimental gene therapy, a new study reports.

Hemophilia B is a rare and inherited genetic disorder in which people have low levels of the

  • By Dennis Thompson HealthDay Reporter
  • |
  • July 22, 2022
  • |
  • Full Page
  • Gene therapy shows promise in reducing, and even halting, potentially life-threatening bleeding events in people with hemophilia, researchers report.

    Hemophilia A is the most common inherited bleeding disorder, affecting one in 5,000 males worldwide. It's caused by a missing coagulation factor called FVIII.

    The current standard of care involves regular infusions of the FVIII protein...

    Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out.

    In what experts called a feat of bioengineering, scientists were able to create a "fusion protein" that may extend the interval between treatments for hemophilia -- from about every couple of days to once a week.

    The early ...

    A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate.

    Patients who received the one-time intravenous therapy continue to have a more than 90% decrease in bleeding events two to three years after their initial treatment, researchers reported Jan. 1 in the New England Journal of Medicine.

    ...